While targeting NRF2 for cancer therapeutics is an active area overall in other cancer types, NRF2 is mainly involved in a subset of type 2 pRCC (i.e., FHpRCC) and NRF2 is an essential target for FHpRCC tumors. Here, NFE2L2 is linked to cancer.